With more than 40 years of experience spanning federal regulatory service, biotechnology leadership, and clinical medical practice, this expert focuses on drug development, health policy, and regulatory oversight, including senior leadership service within a federal public health regulatory agency. He has over 10 years of expert witness experience providing consultation, deposition testimony, and trial testimony in matters involving drug regulation, clinical research, health policy, and medico-legal issues.

His experience encompasses three primary areas: federal drug regulation and policy, including prescription drug advertising and labeling oversight, generic drug approval and bioequivalence review, implementation of federal drug competition legislation, Medicare coverage advising, institutional review board leadership, and postmarketing safety initiatives such as MedWatch; pharmaceutical development and clinical research, including biotechnology strategy, clinical trial supervision, orphan drug processes, Rx-to-OTC switch considerations, reimbursement strategy, HIPAA compliance, and technology transfer; and clinical practice and medical administration, including family medicine and geriatrics practice, corporate medical directorship, emergency physician coverage organization, and collaboration with governmental and professional medical organizations.

He holds M.D., J.D., and M.S. degrees, is board certified by the American Board of Family Medicine with subspecialty certification in Geriatric Medicine, and maintains active licensure in medicine and law. Leadership roles have included executive service in healthcare consulting and biotechnology organizations, chair-level participation on a national drug nomenclature council, and senior administrative appointments within a federal drug regulatory center. Professional affiliations include national organizations in drug information, legal medicine, clinical research, medicine, public health, and law.